**SUPPLEMENTAL TABLE 1.** Adverse Events (frequency) assessed systematically at month one

of the Stage 2 maintenance treatment (among responders to initial Stage 1 acute treatments).

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |  |  |
| --- | --- | --- | --- |
|  | Placebo | Naltrexone/bupropion |  |
| All-Cause Mortality | 0/34 (0%) | 0/32 (0%) |  |
| Serious Adverse Events | 0/34 (0%) | 0/32 (0%) |  |
| Hypertensive Crisis   | 0/34 (0%) | 0/32 (0%) |  |
| Other (Not Including Serious) Adverse Events |
| Constipation   | 5/34 (14.7%) | 10/32 (31.3%) |  |
| Diarrhea   | 5/34 (14.7%) | 2/32 (6.3%) |  |
| Nausea   | 3/34 (8.8%) | 8/32 (25.0%) |  |
| Vomiting   | 3/34 (8.8%) | 3/32 (9.4%) |  |
| Dizziness   | 4/34 (11.8%) | 4/32 (12.5%) |  |
| Dry Mouth   | 3/34 (8.8%) | 10/32 (31.3%) |  |
| Headache   | 4/34 (11.8%) | 9/32 (28.1%) |  |
| Insomnia   | 9/34 (26.5%) | 7/32 (21.9%) |  |
| Anxiety   | 6/34 (17.7%) | 2/32 (6.3%) |  |

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Note: Adverse (side effect) events reported by >5% of participants in either naltrexone/bupropion or placebo treatment conditions during systematic assessment at month one during this maintenance trial. These adverse event data are included in the clinicaltrials.gov record (NCT03047005). We report side effects experienced by >5% of participants in either arm.